Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Free Cash Flow: 2013-2024

Historic Free Cash Flow for Aclaris Therapeutics (ACRS) over the last 12 years, with Dec 2024 value amounting to -$20.2 million.

  • Aclaris Therapeutics' Free Cash Flow fell 149.80% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.0 million, marking a year-over-year decrease of 132.97%. This contributed to the annual value of -$20.2 million for FY2024, which is 74.64% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Free Cash Flow stood at -$20.2 million for FY2024, which was up 74.64% from -$79.6 million recorded in FY2023.
  • Aclaris Therapeutics' 5-year Free Cash Flow high stood at -$20.2 million for FY2024, and its period low was -$79.6 million during FY2023.
  • Its 3-year average for Free Cash Flow is -$56.0 million, with a median of -$68.2 million in 2022.
  • As far as peak fluctuations go, Aclaris Therapeutics' Free Cash Flow crashed by 34.17% in 2021, and later spiked by 74.64% in 2024.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Free Cash Flow stood at -$39.1 million in 2020, then plummeted by 34.17% to -$52.4 million in 2021, then declined by 30.00% to -$68.2 million in 2022, then decreased by 16.81% to -$79.6 million in 2023, then soared by 74.64% to -$20.2 million in 2024.